The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

Br J Haematol. 2018 Jan;180(1):7-8. doi: 10.1111/bjh.15015. Epub 2017 Dec 3.

Authors

Christopher D Gocke¹, Douglas E Gladstone²

Affiliations

¹ Department of Pathology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
² Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

PMID: 29205267
DOI: 10.1111/bjh.15015

No abstract available

Keywords: chronic lymphocytic leukaemia; haematological malignancy; oncological intervention.

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide
Humans
Leukemia, Lymphocytic, Chronic, B-Cell*
Mutation
Rituximab / genetics*
Vidarabine / analogs & derivatives

Substances

Rituximab
Cyclophosphamide
Vidarabine
fludarabine